AWP Litigation: Three More Companies Ink Deals With DoJ; Roxane Sets A Record
Executive Summary
The heavy docket of average wholesale price cases got a bit lighter as three pharma companies agreed to pay $421 million to settle claims they inflated the AWP of numerous drugs, thus increasing reimbursement levels.
You may also be interested in...
AWP Drumbeat Continues With McKesson’s $151 Mil. Medicaid Fraud Settlement With States
The settlement resolves claims McKesson inflated the average wholesale price of more than 1,400 brand drugs.
McKesson Closer To Resolving Multi-Year AWP Legal Saga With $190M Federal Settlement
Wholesale drug distributor McKesson settles charges that it reported inflated average wholesale prices (AWPs) for a large number of branded prescription pharmaceuticals, leading to extensive overpayments by the Medicaid program.
FDA Opened 16 Health Care Fraud Investigations In FY 2011; DoJ Net Tops $4 Billion
HHS and the Department of Justice note actions taken last year in their Health Care Fraud and Abuse Control Program Annual Report for fiscal year 2011; enforcement actions net a record sum.